Metastatic Breast Cancer Symptoms: What to Recognise & When to Act

• Metastatic breast cancer means the cancer has reached distant organs. Bone is the most common site (about 70% of cases), followed by the liver, lungs and brain.
• The classic warning signs are new, persistent and unexplained — deep bone pain that is worse at night, a lasting cough or breathlessness, right-upper-abdomen pain or jaundice, and new neurological symptoms like headaches or seizures.
• Some symptoms are emergencies: leg weakness with bladder or bowel changes (spinal cord compression), new seizures, or sudden confusion all need same-day assessment.
• Hormone-receptor-positive breast cancer can return 5, 10 or 20+ years later, so new persistent symptoms always deserve a look — even long after the 'all clear'.
• Stage 4 is treated as a chronic, controllable disease. Modern hormonal, targeted and immune therapies now let many women live well for years, and palliative care alongside treatment improves both quality of life and, in some studies, survival.

Breast cancer is staged using the TNM system used worldwide and adopted in Indian guidelines from Tata Memorial Hospital and the National Cancer Grid. T describes the size of the primary tumour in the breast, N the involvement of nearby (mostly armpit) lymph nodes, and M distant spread — M0 means no distant spread, M1 means it has reached a far organ. Any M1 finding defines stage 4, or metastatic, breast cancer, regardless of the original tumour size.

The most common sites of spread are bones (involved in roughly 70% of metastatic cases at some point), the liver and lungs (each around 30%), the brain (about 10–20%, more often in HER2-positive and triple-negative disease), and distant lymph nodes. More than one site is common.

The biology of the tumour shapes both where it spreads and how it is treated. Hormone-receptor-positive cancers tend to favour bone and respond to hormonal therapy. HER2-positive cancers more often reach the liver, lungs and brain but are highly sensitive to HER2-targeted drugs. Triple-negative cancers behave more aggressively and can spread early, though targeted options are expanding fast.

Metastasis happens through a multi-step 'cascade': cancer cells invade local tissue, enter blood or lymph vessels, survive in circulation, and seed distant organs. Crucially, cells can break away early and then lie dormant for years to decades before reactivating. This is why hormone-receptor-positive breast cancer can recur 5, 10 or even 20+ years after the original treatment — and why a new, persistent symptom is always worth evaluating, even long after you were declared cancer-free.

Bone is the first place breast cancer spreads in most women who develop metastatic disease, especially in hormone-receptor-positive cancer. The bones most often affected are the spine, pelvis, ribs, skull, the upper thigh bone (femur) and the upper arm bone (humerus) — areas with rich marrow that helps cancer cells take hold.

The most common symptom is bone pain. What sets metastatic bone pain apart from ordinary aches is its pattern:

• Persistent — lasting weeks, not coming and going within hours
• Located in the back, hip, ribs or pelvis (deep, not surface, pain)
• Worse at rest and at night, often waking you from sleep — the opposite of most muscle or joint pain, which eases with rest
• Not relieved by changing position
• Steadily worsening over weeks to months

• Pathological fracture — a bone breaking with little or no injury because cancer has weakened it
• Spinal cord compression — a spine deposit pressing on the spinal cord, causing leg weakness, numbness and bladder or bowel problems. This is an emergency (see the red-flags section)
• High blood calcium (hypercalcaemia) — excessive thirst, frequent urination, constipation, nausea, fatigue and, if severe, confusion
• Low blood counts from marrow involvement — anaemia causing fatigue and breathlessness, easy bruising, or frequent infections

The lungs are one of the three most common sites of spread, affecting roughly 30% of metastatic cases. Cancer can settle in the lung tissue itself (as nodules), in the lining of the lung (the pleura, often producing fluid called a pleural effusion), in chest lymph nodes, or rarely as a diffuse infiltration (lymphangitic carcinomatosis, a more aggressive pattern).

Small lung deposits often cause no symptoms and are picked up on routine surveillance scans. When symptoms do appear, they include:

• A persistent cough lasting more than 2–3 weeks (dry or with phlegm)
• Breathlessness on exertion, progressing to breathlessness at rest as disease advances
• Chest pain, often worse on deep breathing or coughing
• Coughing up blood (haemoptysis) — uncommon, but always worth prompt review
• Chest infections that take longer than usual to clear
• General fatigue and weight loss

The liver is involved in about 30% of metastatic breast cancers. Liver deposits may be single or multiple and are often found on a scan before they cause symptoms. When symptoms appear, they include:

• Aching or pain in the right upper abdomen, sometimes spreading to the right shoulder
• Abdominal fullness, bloating, or feeling full quickly (early satiety)
• Loss of appetite and unexplained weight loss
• Nausea, sometimes with vomiting
• Jaundice — yellowing of the skin and eyes — with pale stools, dark urine and itching, signalling more extensive disease or blocked bile ducts
• Fatigue, and in advanced disease fluid build-up in the abdomen (ascites) causing visible swelling

Brain metastasis affects about 10–20% of women with metastatic breast cancer, with higher rates in HER2-positive and triple-negative disease. Spotting it early matters, because untreated brain deposits can progress quickly.

Symptoms depend on the location, size and number of deposits and on surrounding swelling. They include:

• A new, persistent headache, often worse in the morning, sometimes with nausea or vomiting — different in character from an ordinary migraine or tension headache
• New seizures (focal or generalised)
• Progressive weakness or numbness on one side of the body
• Difficulty with speech or language
• Vision changes — double vision, blurring, or loss of part of the visual field
• Unsteady walking, poor balance or coordination
• Memory problems, confusion, slowed thinking or trouble concentrating
• Subtle personality or behaviour changes
• Nausea and vomiting with no stomach cause, or reduced alertness in severe cases

Diagnosing metastatic breast cancer means confirming the suspicion, mapping every site involved, characterising the tumour biology, and setting a baseline to measure treatment against.

The workup usually includes a full history and examination; blood tests (full blood count, calcium and liver function, and tumour markers CA 15-3 and CEA — useful for tracking trends, not for diagnosis alone); staging imaging (CT chest and abdomen, bone scan, brain MRI if symptoms suggest it, and increasingly whole-body PET-CT); and a tissue biopsy of a metastatic site wherever feasible.

That biopsy is important because the receptor status can change. Around 15–20% of recurrences differ from the original cancer for ER, more for PR, and 5–15% for HER2. The implications are direct: a deposit that has become HER2-positive is now eligible for HER2-targeted therapy; one that has become hormone-receptor-positive becomes eligible for hormonal therapy. NCCN, ESMO, ASCO and Tata Memorial guidelines all recommend re-biopsy where feasible, especially after a long disease-free interval. The receptor concept is the same one explained in our overview of breast cancer detection and treatment.

Liquid biopsy — analysing tumour DNA shed into the blood — can detect mutations that guide therapy (such as PIK3CA and ESR1) and is increasingly offered at major Indian oncology centres. If breast cancer runs in your family, BRCA gene testing can identify mutations that both shape treatment (PARP inhibitors) and affect ovarian cancer risk and screening for relatives.

Within stage 4, prognosis varies with the sites and amount of disease (bone-only disease generally does better than visceral organ involvement), the subtype, the time since the original cancer, and overall health. Re-staging scans every 3–6 months (or sooner if there is concern) track response and guide changes in therapy. Comprehensive evaluation and treatment are available at Tata Memorial Hospital, AIIMS, CMC Vellore, PGIMER, regional cancer centres and major private oncology networks (Apollo, Manipal, Fortis, HCG and others).

Treatment for metastatic breast cancer has been transformed in the last decade. The modern framework treats it as a chronic, controllable disease: a true cure remains uncommon, but median survival has improved substantially, and many women live for years — sometimes more than a decade — often with good quality of life.

Hormone-receptor-positive, HER2-negative disease (the most common type) is treated first with an aromatase inhibitor (letrozole, anastrozole or exemestane) plus a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib — all available in India), a combination that roughly doubled progression-free survival in landmark trials. Later lines include fulvestrant, alpelisib for PIK3CA-mutated tumours, elacestrant for ESR1-mutant disease, mTOR inhibitors, and ultimately chemotherapy.

HER2-positive disease is treated with HER2-targeted drugs: dual blockade with trastuzumab and pertuzumab plus chemotherapy first line, then trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (a major advance), and tucatinib-based combinations with brain activity.

Triple-negative disease is increasingly tailored: immunotherapy (pembrolizumab) with chemotherapy for PD-L1-positive tumours, PARP inhibitors (olaparib, talazoparib) for BRCA-mutated tumours, and the antibody-drug conjugate sacituzumab govitecan.

Local radiotherapy, bone-strengthening agents and — importantly — palliative care integrated alongside active treatment (not only at the end of life) all add to quality of life and, in some studies, survival. Indian palliative services have grown through Pallium India (Kerala), Cipla Palliative Care, and hospital teams at Tata Memorial and AIIMS.

Living with stage 4 disease means ongoing therapy, periodic scans, symptom and side-effect management, and emotional support. The weight of a stage 4 diagnosis, scan-result anxiety and grief over altered plans are real — mental health support is part of cancer care, not an extra. For younger women, conversations about fertility preservation before treatment matter where relevant. Many women continue work, family life and meaningful activities for years. Support is available through the Indian Cancer Society, Pink Hope, Pink Initiative and online communities.

Most aches and minor symptoms are not cancer. But if you have a history of breast cancer — or new symptoms you cannot explain — book a review for any of these:

• New, persistent bone pain that is deep, worse at night, wakes you from sleep, or does not improve with rest
• A cough or breathlessness lasting more than 2–3 weeks, or coughing up blood
• Right-upper-abdomen pain, jaundice (yellowing), persistent nausea, or unexplained weight loss
• A new persistent headache (especially worse in the morning) or any new neurological change
• A new breast or armpit lump, skin change, or unusual nipple discharge — also worth checking with regular breast self-awareness

• Leg weakness or numbness with new bladder or bowel problems — possible spinal cord compression, which needs treatment within hours to protect nerve function
• A first-ever seizure, sudden confusion, or a sudden severe change in alertness
• Severe thirst, drowsiness and confusion together — possible high blood calcium
• Sudden severe breathlessness or chest pain

• World Health Organization — Breast cancer fact sheet
• National Comprehensive Cancer Network (NCCN) Guidelines — Breast Cancer
• ESMO Clinical Practice Guidelines — Metastatic Breast Cancer
• Tata Memorial Centre — Evidence Based Management of Cancers in India
• National Cancer Institute — Metastatic Cancer
• Pallium India — Palliative care resources